Ipamorelin

Overview

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk in the mid-1990s. It belongs to a class of compounds that stimulate growth hormone release by acting on the growth hormone secretagogue receptor (GHSR, also known as the ghrelin receptor). Ipamorelin is distinguished from other GH secretagogues by its notable selectivity for growth hormone release without significantly affecting other pituitary hormones.

Unlike earlier growth hormone releasing peptides such as GHRP-6 and GHRP-2, Ipamorelin does not cause significant increases in cortisol, prolactin, or adrenocorticotropic hormone (ACTH) at GH-stimulating doses. This selectivity profile has made it one of the most extensively studied GH secretagogues in both preclinical and clinical settings, with particular interest in its potential for growth hormone deficiency, age-related sarcopenia, and post-surgical recovery.

The peptide was advanced through Phase II clinical trials for postoperative ileus (delayed return of bowel function after surgery), conducted under the name NNC 26-0161. While the development program was ultimately discontinued, the clinical data generated provided valuable insights into the pharmacology and safety of selective GH secretagogues.

Mechanism of Action

Ipamorelin exerts its effects through highly selective agonism of the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor targeted by the endogenous hormone ghrelin.

Selective GHSR Agonism

The GHS-R1a is a seven-transmembrane G-protein coupled receptor expressed in the hypothalamus and anterior pituitary. When activated by Ipamorelin, it triggers a Gq/11-phospholipase C-IP3 signaling cascade that raises intracellular calcium, stimulating GH release from somatotrophs. The key distinction of Ipamorelin is its narrow binding profile: it activates GHS-R1a without engaging other receptor subtypes or pathways that stimulate ACTH or prolactin secretion.

Synergy with GHRH Pathway

Ipamorelin acts synergistically with endogenous GHRH and its analogs (such as CJC-1295 and Mod GRF 1-29). While GHRH activates the cAMP-PKA pathway in somatotrophs, Ipamorelin activates the IP3-calcium pathway. These complementary mechanisms produce a greater GH response when combined than either agent alone, which is why the Ipamorelin/CJC-1295 combination has been widely studied in research contexts.

Dose-Dependent Response

Research has shown that Ipamorelin produces a dose-dependent, bell-shaped GH response curve. At optimal doses, it produces robust GH pulses with a rapid onset (peak at approximately 40 minutes post-injection) and relatively short duration, allowing for multiple daily administrations that mimic natural pulsatile GH secretion patterns.

Research Summary

Selectivity Studies

Raun et al. (1998), publishing in the European Journal of Endocrinology, conducted the landmark characterization of Ipamorelin’s selectivity. In swine models, Ipamorelin stimulated GH release in a dose-dependent manner comparable to GHRP-6, but unlike GHRP-6, it did not affect plasma ACTH or cortisol levels even at doses 200 times the effective GH-releasing dose. This study established Ipamorelin as the first truly selective GH secretagogue.

Postoperative Ileus Clinical Trials

Beck et al. (2008), in research published in the Journal of Surgical Research, reported results from a Phase II clinical trial of Ipamorelin for postoperative ileus following abdominal surgery. Intravenous Ipamorelin (0.03 mg/kg) significantly accelerated the time to first bowel movement and was well-tolerated with minimal adverse effects. A larger Phase IIb trial was conducted by Helsinn Healthcare but did not meet its primary endpoints, leading to discontinuation of development for this indication.

Bone Metabolism

Andersen et al. (2001), publishing in Bone, investigated the effects of Ipamorelin on bone formation in ovariectomized rats, a model for postmenopausal osteoporosis. Systemic administration of Ipamorelin for 12 weeks increased bone mineral content, bone formation rate, and periosteal mineral apposition rate, suggesting anabolic effects on bone that were mediated through sustained GH/IGF-1 elevation.

Growth Hormone Kinetics

Johansen et al. (1999), in Growth Hormone & IGF Research, performed detailed pharmacokinetic and pharmacodynamic analyses of Ipamorelin in healthy male volunteers. Subcutaneous injection of 1 mcg/kg produced peak GH levels of approximately 30 mcg/L at 40 minutes post-dose, with GH levels returning to baseline within 2-3 hours. No tachyphylaxis was observed with repeated dosing over 7 days.

Dosing in Published Research

Ipamorelin is a synthetic growth-hormone secretagogue. It is not an approved medicine and has no labeled dose. Its most substantial human evaluation was a Phase 2 trial of postoperative ileus (ClinicalTrials.gov NCT00672074, sponsored by Helsinn), in which patients received intravenous ipamorelin at 0.03 mg per kilogram of body weight twice daily. The compound was not advanced to approval for that indication. These figures describe what was administered in that specific trial.

Safety and Side Effects

Ipamorelin has not been established as safe through completed clinical development. It is a growth hormone secretagogue, and its anticipated adverse effects follow from raising growth hormone and IGF-1: fluid retention, transient changes in insulin sensitivity and blood glucose, headache, and injection-site reactions. Ipamorelin is described as more selective than GHRP-6 and GHRP-2, with less stimulation of cortisol and prolactin, but selectivity reduces rather than eliminates off-target effects, and the sustained elevation of growth hormone and IGF-1 carries the same theoretical proliferative and metabolic concerns as other secretagogues. Long-term human safety data do not exist, and material sold as a research chemical is of uncertain identity and purity.

Current Research Status

Ipamorelin was investigated in early clinical studies, including for postoperative ileus, but was not advanced to regulatory approval; it is not approved by the FDA or any major regulatory agency. It is prohibited in sport by the World Anti-Doping Agency. It remains an investigational compound sold only through unregulated research-chemical channels.

Frequently Asked Questions